Clinical Study of Risk Factors for Diabetic Maculopathy

Aim:To determine the association between various systemic risk factors with diabetic maculopathy. Methodology:A prospective observational study was conducted on 50 patients having diabetic maculopathy. Patients with maculopathies secondary to Vitreous Haemorrhage, Ocular disorders like Glaucoma, Uveitis, Advanced Diabetic Eye Disease, Vitreo-macular traction, maculopathy along with proliferative diabetic retinopathy, ischemic maculopathy, and history of laser treatment in last six months were excluded from the study. Data was collected using a structured proforma that included name, age, sex, occupation, height, weight, history of other systemic diseases like hypertension, investigations and treatment taken in past, family history, duration of DM, smoking, hyperlipidemia, hyperglycemia and nephropathy. Results:Out of 50 patients, 38 (76%) were males and 12 (24%) were females suggestive of male predominance. Mean age of the patient was 57.36±11.65 years in males and 56.67±10.17 years in females. Among 50 patients, 19 patients had diabetes mellitus for 6-10 years duration, 14 patients had diabetes mellitus for 1-5 years, in 12 patients for 11-15 years, in 2 patients for 16-20 years, in 2 patients for 21-25 years and only 1 patient more than 25 years. Mean duration of DM was 12.2±6.1 years. Majority of patients having maculopathy had duration of DM up to 20 years. Among 50 patients, 27 patients (54%) had systemic hypertension, 37 patients (74%) had uncontrolled blood sugar level, 29 patients (58%) were found to have hyperlipidemia and 20 patients (40%) had nephropathy. Among 50 patients, pseudophakia was noted in 7 patients (14%), obesity was noted in 21patients (42%). Eleven patients (22%) were found to have anemia, 6 patients (12%) had family history of DM and 13 patients (26%) had history of smoking. Conclusion: Hyperglycemia, hypertension, duration of DM, hyperlipidemia are the major risk factors for the development and progression of diabetic maculopathy. While anemia, smoking, obesity and family history of DM is the less signi?cant risk factors

Caracterización clínica y epidemiológica de la maculopatía diabética en adultos de 50 años y más en Cuba / Clinical and epidemiological characterization of diabetic maculopathy in adults aged 50 years and over in Cuba

RESUMEN Objetivo: Determinar las características clínicas y epidemiológicas de la maculopatía diabética en adultos de 50 años y más en Cuba. Métodos: Se realizó una investigación epidemiológica, descriptiva transversal, que tomó la Encuesta Rápida de Ceguera Evitable realizada en Cuba en el año 2016, la cual incluyó la retinopatía diabética validada por la Organización Mundial de la Salud. Resultados: La prevalencia de cualquier grado de maculopatía fue de 8,5 por ciento (6,1 a 10,8) y la maculopatía observable y remitible fue de 4,2 por ciento (2,2 a 6,0). El riesgo de desarrollar maculopatía resultó mayor en el sexo femenino, con el 9,3 por ciento (6,6-12,9), y en los diabéticos que tenían entre 60 y 69 años de edad, de 9,2 por ciento (5,7-14,0). Este riesgo se incrementaba si existía descontrol de la glicemia y si la enfermedad tenía 15 años y más de evolución. La asociación con la retinopatía observable fue de 2,5 por ciento. La discapacidad visual moderada por maculopatía fue de 1,4 % y la grave junto con la ceguera de 0,8 por ciento. La cobertura de tratamiento fue baja (28,6 por ciento por personas). Conclusiones: El diabético de 50 años y más en Cuba tiene baja prevalencia de maculopatía diabética, la cual se comporta de manera similar para la forma observable y para la remitible. La retinopatía no proliferativa moderada tiene mayor riesgo de afectación macular. La discapacidad visual por afectación macular en el diabético es baja, aunque la estrategia de atención oftalmológica en el diabético no alcanza los estándares necesarios de efectividad, relacionados con la cobertura del tratamiento con láser(AU)

ABSTRACT Objective: Determine the clinical and epidemiological characteristics of diabetic maculopathy in adults aged 50 years and over in Cuba. Methods: A descriptive cross-sectional epidemiological study was conducted based on the Rapid Assessment of Avoidable Blindness survey developed in Cuba in the year 2016, which included diabetic retinopathy with validation by the World Health Organization. Results: Prevalence of any maculopathy grade was 8.5 percent (6.1 to 10.8), whereas observable, referable maculopathy was 4.2 percent (2.2 to 6.0). Risk for maculopathy was higher in the female sex with 9.3 percent (6.6-12.9) and among diabetics from the 60-69 years age group with 9.2 percent (5.7-14.0). Risk increased in uncontrolled glycemia and when the evolution of the disease was 15 years and over. Association with observable retinopathy was 2.5 percent. Moderate visual disability due to maculopathy was 1.4 percent, while severe disability and blindness were 0.8 percent. Treatment coverage was low (28.6 percent per persons). Conclusion: Prevalence of maculopathy is low among diabetics aged 50 years and over in Cuba, with similar behavior in the observable and the referable variants. Moderate non-proliferative retinopathy shows a higher risk for macular damage. Visual disability due to macular damage is low among diabetics, though the ophthalmological care strategy for diabetics does not achieve the required effectiveness standards in terms of laser therapy coverage(AU)

Analyzing the Effect of Single Intraoperative Intravitreal Bevacizumab on Central Macular Thickness in Diabetes Mellitus Patients Undergoing Phacoemulsification Under Local Anesthesia

Aim: The aim of the study was to assess the effect of combined phacoemulsification and single intraoperative intravitrealinjection of bevacizumab on the central macular thickness (CMT) in diabetic patients.Materials and Methods: A prospective observational study was conducted on 30 eyes with diabetic retinopathy from February2018 to February 2019. All patients underwent thorough ophthalmic evaluation. Phacoemulsification performed by a singlesurgeon using either 0.5% topical proparacaine eye drops or sub-tenon local anesthesia as per the preference of the surgeonin individual case. Bevacizumab 0.05 ml (1.25 mg) was injected intravitreal using a 30-gauge needle through the pars planainto the vitreous cavity after intraocular lens implantation. Patients were followed postoperatively at day 1 then at 1 week and1 month, respectively, for recording the CMT and best corrected visual acuity at 1 month postoperatively.Results: The mean CMT for all the patients at post-operative day 1 and month 1 was 277.96 ± 142.40 μm and 289.50 ± 155.74 μm,respectively. Patients with <10 years of diabetes had mean CMT of 329.09 μm and 318.90 μm, at post-operative day 1 and at1 month, respectively, while those with diabetes more than 10 years had mean CMT of 248.36 μm and 272.47 μm, respectively.In mild non-proliferative diabetic retinopathy (NPDR) and stable proliferative diabetic retinopathy group no significant worseningoccurred in CMT thickness, while in moderate NPDR, four out of 13 cases showed significant increase in CMT (>10%) at 1 month. Insevere NPDR, out of 4 cases 1 case showed significant increase in CMT while other three cases showed modest reduction of CMT.Conclusion: Intravitreal administration of 1.25 mg bevacizumab at the time of cataract surgery is a safe and effective way inavoiding new onset maculopathy in diabetic retinopathy patients. It is also effective to treat pre-existing clinically significantmacular edema and prevent its progression to some extent in few cases.

Predicting postoperative visual outcomes in cataract patients with maculopathy.

Purpose: To assess the accuracy of the potential acuity meter (PAM) in predicting postcataract surgery visual acuity outcome in patients with healed inactive maculopathies. Study Design: Prospective interventional clinical trial. Patients and Methods: Patients scheduled for phacoemulsification had preoperative and 1 month postoperative best‑corrected visual acuity (BCVA), PAM test, fluorescein angiography, and macular optical coherence tomography. Patients were grouped to following preoperative BCVA: PRE1: 0.29 and better, PRE2: 0.25–0.13, and PRE3: 0.1 or worse; age: G1 <60, G2 = 60–70, and G3 >70 years. PAM accuracy was divided into: Grade 1: Postoperative BCVA ≤1 or less line error of the PAM score, Grade 2: Between 1 and 2 lines error, and Grade 3: ≥3 lines or more error. Results: This study enrolled 57 patients with a mean age of 71.05 ± 6.78 years where 34 were females. There were 21 (36.84%) patients with diabetic maculopathy and 36 (63.16%) with age‑related macular degeneration. The mean preoperative BCVA was 0.198 ± 0.12 (0.1–0.5). The mean PAM score was 0.442 ± 0.24 (0.1–1.3). The mean postoperative BCVA was 0.4352 ± 0.19 (0.17–1.00). The PAM score was in Grade 1, 2, and 3 in 46 (80.7%), 54 (94.7%), and 56 (98.2), respectively. There was a highly significant correlation between the PAM score and the postoperative BCVA (P < 0.001, Chi‑square test). There was no correlation between the PAM test accuracy and age, gender, diagnosis, and preoperative BCVA (P = 0.661, 0.667, 0. 0.991, 0.833, Chi‑square test; respectively). Conclusion: The PAM is an accurate method of predicting postoperative visual acuity for eyes with nuclear cataracts Grade I and II and inactive maculopathies.

Evaluation of Macular Circulation in Patient with Diabetic Maculopathy using Scanning Laser Ophthalmoscope(SLO)

In the condition of diabetic retinopathy, the vascular changes are localized primarily in the retinal capillaries and are presumed to promote angiogenesis. To investigate the change of retinal blood flow velocities and morphological parameters in diabetic retinopathy, we measured perifoveal capillary blood velocities(v) and the size of foveal avascular zones(FAZ). Thirteen patients with diabetic maculopathy and nine healthy volunteers were included in this study. The scanning laser technique in conjunction with an image analysing system were used to assess the morphological and hemodynamic changes in diabetic retinopathy. Diabetic maculopathy group showed a slower capillary blood velocity than normal group(2.44+/-0.39mm/sec vs2.75+/-0.61 mm/sec, p>0.18). The foveal avascular zone was significantly larger in diabetic maculopathy group than in normal group(313.5+/-64.6micrometervs. 238.9+/-93.8micrometer, p<0.05). This results indicate that the retinal microcirculation is altered in diabetic patients compared with healthy subjects. These alterations may be due to the change of the capillary wall and blood viscosity in diabetic patients. The determination of these parameters can be utilized in monitoring the progress of diabetic maculopathy.

Clinical Analysis on Focal Laser Treatment of Diabetic Maculopathy

Diabetic maculopathy which is the major cause of blindness in nonproliferative diabetic retinopathy, has been treated clinically with laser photocoagulation. We reviewed 21 cases(26 eyes) of diabetic maculopathy which were treated by focal laser treatment and followed up for more than 6 months from January 1984 to December 1988. The results were as follows: 1. There was improvement of the visual acuity in 19 eyes(71.1%), no changes in 5 eyes(19.2%), and only two eyes(7.7%) showed worsened visual acuity. 2. The two eyes which showed worsened visula acuity after treatment showed stage IV of diabetic maculopathy.